First Trust Advisors LP Raises Stock Holdings in UiPath Inc. (NYSE:PATH)

First Trust Advisors LP lifted its stake in shares of UiPath Inc. (NYSE:PATHFree Report) by 122.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,132,984 shares of the healthcare company’s stock after acquiring an additional 624,003 shares during the quarter. First Trust Advisors LP owned approximately 0.20% of UiPath worth $28,143,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Stephens Investment Management Group LLC boosted its position in shares of UiPath by 1.1% in the fourth quarter. Stephens Investment Management Group LLC now owns 153,603 shares of the healthcare company’s stock worth $3,815,000 after purchasing an additional 1,666 shares during the period. KBC Group NV raised its stake in UiPath by 22.0% during the 4th quarter. KBC Group NV now owns 55,880 shares of the healthcare company’s stock valued at $1,388,000 after purchasing an additional 10,068 shares during the period. California State Teachers Retirement System raised its stake in UiPath by 5.3% during the 4th quarter. California State Teachers Retirement System now owns 565,216 shares of the healthcare company’s stock valued at $14,040,000 after purchasing an additional 28,435 shares during the period. Qtron Investments LLC bought a new position in UiPath in the 4th quarter worth approximately $231,000. Finally, Burkett Financial Services LLC purchased a new stake in UiPath during the 4th quarter valued at approximately $74,000. 62.50% of the stock is owned by hedge funds and other institutional investors.

UiPath Stock Up 0.1 %

Shares of UiPath stock opened at $12.01 on Tuesday. The company has a 50 day moving average price of $18.63 and a 200 day moving average price of $21.81. The firm has a market capitalization of $6.83 billion, a P/E ratio of -75.06 and a beta of 0.85. UiPath Inc. has a 52 week low of $11.53 and a 52 week high of $27.87.

UiPath (NYSE:PATHGet Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.10. UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. The business had revenue of $405.25 million during the quarter, compared to the consensus estimate of $383.32 million. As a group, research analysts anticipate that UiPath Inc. will post -0.2 earnings per share for the current fiscal year.

Insider Buying and Selling at UiPath

In related news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the sale, the chief financial officer now owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders have sold 96,000 shares of company stock worth $2,023,440. 22.37% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on PATH shares. JPMorgan Chase & Co. lowered their target price on shares of UiPath from $28.00 to $19.00 and set an “overweight” rating on the stock in a report on Thursday, May 30th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $29.00 price target on shares of UiPath in a research note on Monday, April 1st. Scotiabank dropped their price objective on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating for the company in a report on Wednesday, May 29th. Barclays reduced their target price on UiPath from $25.00 to $16.00 and set an “equal weight” rating on the stock in a report on Thursday, May 30th. Finally, Needham & Company LLC reissued a “hold” rating on shares of UiPath in a research note on Thursday, May 30th. Sixteen analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $18.12.

Check Out Our Latest Research Report on PATH

UiPath Profile

(Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Stories

Institutional Ownership by Quarter for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.